{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:00:13Z","timestamp":1786993213117,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003397","name":"Huazhong University of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jpba.2021.114072","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T02:56:23Z","timestamp":1618541783000},"page":"114072","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Isolation, structural characterization and quality control strategy of an unknown process-related impurity in sugammadex sodium"],"prefix":"10.1016","volume":"200","author":[{"given":"Tao","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cangcang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bifeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guisen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2021.114072_bib0005","first-page":"266","article-title":"A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host","volume":"41","author":"Bom","year":"2002","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jpba.2021.114072_bib0010","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1021\/jm011107f","article-title":"Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships","volume":"45","author":"Adam","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpba.2021.114072_bib0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1586\/17512433.2.1.37","article-title":"Sugammadex: a novel selective relaxant binding agent","volume":"2","author":"Naguib","year":"2009","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2021.114072_bib0020","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s40265-016-0604-1","article-title":"Sugammadex: a review of neuromuscular blockade reversal","volume":"76","author":"Keating","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2021.114072_bib0025","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1213\/01.ane.0000244594.63318.fc","article-title":"Sugammadex: another milestone in clinical neuromuscular pharmacology","volume":"104","author":"Mohamed","year":"2007","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.jpba.2021.114072_bib0030","series-title":"Process for Preparation of Sugammadex, US9120876 (B2)","author":"Davuluri","year":"2015"},{"key":"10.1016\/j.jpba.2021.114072_bib0035","series-title":"Process for Preparation of Sugammadex Sodium, US9879096 (B2)","author":"Ravi","year":"2018"},{"key":"10.1016\/j.jpba.2021.114072_bib0040","series-title":"Preparation Method for Sugammadex Sodium, CN104844732 (B)","author":"Chen","year":"2015"},{"key":"10.1016\/j.jpba.2021.114072_bib0045","series-title":"Process for the Preparation of Sugammadex, US10577433 (B2)","author":"Cabri","year":"2020"},{"key":"10.1016\/j.jpba.2021.114072_bib0050","series-title":"An Improved Process for the Preparation of Sugammadex, CN105348412 (A)","author":"Chen","year":"2016"},{"key":"10.1016\/j.jpba.2021.114072_bib0055","series-title":"Processes for the Preparation of Sugammadex, WO2019236436 (A1)","author":"Jamie","year":"2019"},{"key":"10.1016\/j.jpba.2021.114072_bib0060","series-title":"Novel Process for the Purification of Sugammadex Sodium, WO2020121207 (A1)","author":"Pullagurla","year":"2020"},{"key":"10.1016\/j.jpba.2021.114072_bib0065","series-title":"Sugammadex Sodium Related Substances, and Preparation Method and Applications Thereof, CN110627926 (A)","author":"Gao","year":"2019"},{"key":"10.1016\/j.jpba.2021.114072_bib0070","series-title":"Sugammadex Sodium Diphenylphosphine Oxide Derivative Impurity and Preparation Method Thereof, CN110818817 (A)","author":"Ma","year":"2020"},{"key":"10.1016\/j.jpba.2021.114072_bib0075","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3389\/fphar.2017.00403","article-title":"Embryo and developmental toxicity of cefazolin sodium impurities in zebrafish","volume":"8","author":"Chen","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jpba.2021.114072_bib0080","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0731-7085(01)00550-7","article-title":"The isolation and identification of a toxic impurity in XP315 drug substance","volume":"27","author":"Sigvardson","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2021.114072_bib0085","series-title":"International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Q3A (R2), Impurities in New Drug Substances","first-page":"1","year":"2006"},{"key":"10.1016\/j.jpba.2021.114072_bib0090","series-title":"NMR Data Interpretation Explained: Understanding 1D and 2D NMR Spectra of Organic Compounds and Natural Products","first-page":"151","author":"Jacobsen","year":"2016"},{"key":"10.1016\/j.jpba.2021.114072_bib0095","series-title":"Method for Producing 3-mercaptopropionic Acid, and Methods Using Same for Producing Carboxylic Acid Ester Compound Having Mercapto Group and Thiourethane-based Optical Material, US20180179154 (A1)","author":"Jang","year":"2018"},{"key":"10.1016\/j.jpba.2021.114072_bib0100","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jpba.2018.01.026","article-title":"Isolation, identification and characterization of two novel process-related impurities in olanzapine","volume":"152","author":"Zhuang","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2021.114072_bib0105","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jpba.2017.02.012","article-title":"Identification, characterization and in silico ADMET prediction of Roflumilast degradation products","volume":"138","author":"Pinheiro","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2021.114072_bib0110","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jpba.2018.10.050","article-title":"In vitro and in vivo investigation of metabolic fate of riociguat by HPLC-Q-TOF\/MS\/MS and in silico evaluation of the metabolites by ADMET predictor\u2122","volume":"164","author":"Tiwari","year":"2019","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521001837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521001837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:12:15Z","timestamp":1760001135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708521001837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":22,"alternative-id":["S0731708521001837"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114072","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isolation, structural characterization and quality control strategy of an unknown process-related impurity in sugammadex sodium","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114072"}}